Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(10), P. 3422 - 3422

Published: May 14, 2025

The interplay between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and viral hepatitis, primarily hepatitis B virus (HBV) C (HCV), presents a complex challenge in managing chronic liver diseases. Recent epidemiological insights suggest an escalating prevalence of MASLD globally, attributed mainly to the obesity epidemic associated metabolic disorders. Concurrently, remains significant contributor disease morbidity mortality worldwide, despite advances antiviral therapies. According World Health Organization (WHO) 2023 data, approximately 296 million people are living with HBV infection (about 3.8% global population), 58 HCV 0.7%), together accounting for over 1.1 deaths annually. coexistence scenario clinical outcomes, where effects on health can vary. Although many studies highlight potential additive or synergistic worsening conditions, leading complications such as cirrhosis, failure, HCC, impact is not consistent. Managing patients dual due factors. Lifestyle modifications, including weight loss, dietary changes, physical activity, fundamental management help reduce fibrosis risk hepatitis. This review examines pathology delineates shared pathophysiological mechanisms, influence hepatic steatosis, inflammation, fibrogenesis. It also discusses therapeutic strategies tailored manage this comorbidity, emphasizing need integrated care approach that addresses both dysfunctions optimize patient outcomes.

Language: Английский